{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-025667","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2026-06-18T12:01:22+00:00","discovered_at":"2026-06-18T12:05:00.232041+00:00","generated_at":"2026-06-18T12:05:20.215109+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Grace Therapeutics FY2026 net loss $7.8M; FDA CRL for GTx-104; Type A meeting set","bullets":["Net loss of $7.8M ($0.47 loss per share) for FY2026, improved from $9.6M loss in FY2025.","Cash and equivalents $17.0M at March 31, 2026; expected to fund operations at least 12 months.","FDA issued Complete Response Letter for GTx-104 NDA in April 2026; no clinical deficiencies cited; Type A meeting scheduled.","Phase 3 STRIVE-ON trial met primary endpoint; 19% reduction in clinically significant hypotension vs oral nimodipine.","New U.S. patent (No. 12,414,943) for IV dosing regimen extends GTx-104 IP protection to 2043."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-025667","json":"https://secwatch.observer/filing/0001140361-26-025667.json","markdown":"https://secwatch.observer/filing/0001140361-26-025667.md","text":"https://secwatch.observer/filing/0001140361-26-025667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/0001140361-26-025667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:05:20.215109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20d275788f2be9fccd6421acbc843bdcfd6d8bdf","claim":"Grace Therapeutics, Inc. reported the fiscal year ended March 31, 2026 results: net income net loss of $7.8 million, EPS $0.47 loss per share.","evidence_excerpt":"The Company reported a net loss of $7.8 million, or $0.47 loss per share for the fiscal year ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/0001140361-26-025667-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended March 31, 2026"},{"label":"Net income","value":"net loss of $7.8 million"},{"label":"EPS","value":"$0.47 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}